Market Place
Sourcing Support
TaiGen’s partner, Joincare completes influenza antiviral TG-1000 phase III study
19 Apr 2024 //
PHARMABIZ
TaiGen Successfully Completes TG-1000 Phase III Study
17 Apr 2024 //
PR NEWSWIRE
TaiGen Enters Exclusive License Agreement with YSP
10 Oct 2023 //
PR NEWSWIRE
TaiGen Enters Exclusive License Agreement with Joincare for TG-1000 in China
22 Mar 2023 //
PR NEWSWIRE
Taiwan`s TaiGen Biotech takes pan-influenza antiviral drug to China
22 Mar 2023 //
BIOSPECTRUM ASIA
TaiGen Partners with GPCR to develop Burixafor & Taigexyn®
09 Nov 2020 //
PRNASIA
TaiGen Announces FDA Approval of IND for Its Flu Antiviral TG-1000
02 Nov 2020 //
PRNEWSWIRE
TaiGen Announces FDA Approval of IND for Its Flu Antiviral TG-1000
02 Nov 2020 //
PRNASIA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.